Replies to post #115151 on Cannabis Science Inc (fka CBIS)

[Palo]

10. SUBSEQUENT EVENTS

On July 16, 2015, the Company issued a total of 10,000,000 common shares to executives and various consultants pursuant to existing contracts.


On September 2, 2015, the Company increased the number of authorized shares of common stock from 1,500,000,000 to 3,000,000,000.

On September 2, 2015, the Company approved dividend paid in the form of common stocks and warrants.


http://ih.advfn.com/p.php?pid=nmona&article=68829794

[Palo]

On July 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.

On July 17, 2015 Cannabis Science announced a key member of its scientific advisory board, Harold C. Smith, Ph.D., Professor in Biochemistry, Biophysics, and Oncology and the Center for RNA Biology at the University of Rochester, School of Dentistry and Medicine, have prepared the blueprint for establishing basic science exploration and explanation for medicinal benefits associated with cannabinoid products. The goal will be evaluate, through scientific proven methods, cellular responses to cannabinoids that can be correlated and eventually directly ascribed as the 'drug-targets'.

On July 23, 2015 Cannabis Science announced the addition of Mark Wainberg, Ph.D., Director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and Professor of Medicine and of Microbiology at McGill University.

On July 29, 2015 Cannabis Science announced the addition of Dr. Gary Blick, MD to their Scientific Advisory Board. The Company is currently focused on the development of novel therapies to treat HIV and HIV-related Kaposi Sarcoma with its CS-TATI-1 preclinical drug in development by utilizing Cannabinoid based formulations.

On August 10, 2015 Cannabis Science announced that the initial California products have been released through their agreement with the Cannabis Science Research Foundation. The initial release is for test marketing, and results will be used for additional large-scale rollouts. The CBIS Brand is being sold in multiple locations in California; there are currently at least three or four public and private dispensaries to acquire the products. The website will be updated on a weekly basis as more California locations and more diverse CBIS Products come online. Current Public locations that CBIS California Products can be found are: Hidden Leaf Organics 5009 Melrose Ave. Los Angeles, CA 90038 323.822.5135 and Cannacanhelp Inc (Formerly CCIC) 6614 Ave 304 Goshen, CA 93227.